{"title":"通过氨基酸诱导的蛋白A亲和层析的pH值变化增强治疗性抗体的产生。","authors":"Senzhu Lin, Yue Wang","doi":"10.3389/fbioe.2025.1567923","DOIUrl":null,"url":null,"abstract":"<p><p>Protein aggregation, denaturation, and loss of potency often occur during Protein A chromatography due to the harsh acidic conditions required for antibody elution. This study presents a pH shift-based elution strategy that effectively mitigates these issues by introducing amino acid-based elution buffers to create a milder elution environment and increase the final elution pH. By optimizing the combination of pre-elution and elution buffers, the elution pool pH was increased up to 7.2, significantly enhancing protein stability. Among various elution buffers tested, amino acids with non-polar or polar uncharged side chains-such as leucine, glycine, and serine-exhibited the most effective pH transition, resulting in 0.5-2.9 units pH shifts. Additionally, the use of 50 mM Bis-Tris, pH 7.2 as a pre-elution buffer demonstrated the highest capacity for stabilizing pH shifts. The scalability of this approach was validated using a 10 cm diameter column, where yields remained comparable to small-scale experiments, and elution pool stability was able to be maintained for 72 h at 26°C. These findings establish pH-shifting elution as a scalable, cost-effective method for improving the recovery and stability of low pH-unstable therapeutic antibodies in Protein A chromatography.</p>","PeriodicalId":12444,"journal":{"name":"Frontiers in Bioengineering and Biotechnology","volume":"13 ","pages":"1567923"},"PeriodicalIF":4.3000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006759/pdf/","citationCount":"0","resultStr":"{\"title\":\"Enhancing therapeutic antibody production through amino acid-induced pH shift in Protein A affinity chromatography.\",\"authors\":\"Senzhu Lin, Yue Wang\",\"doi\":\"10.3389/fbioe.2025.1567923\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Protein aggregation, denaturation, and loss of potency often occur during Protein A chromatography due to the harsh acidic conditions required for antibody elution. This study presents a pH shift-based elution strategy that effectively mitigates these issues by introducing amino acid-based elution buffers to create a milder elution environment and increase the final elution pH. By optimizing the combination of pre-elution and elution buffers, the elution pool pH was increased up to 7.2, significantly enhancing protein stability. Among various elution buffers tested, amino acids with non-polar or polar uncharged side chains-such as leucine, glycine, and serine-exhibited the most effective pH transition, resulting in 0.5-2.9 units pH shifts. Additionally, the use of 50 mM Bis-Tris, pH 7.2 as a pre-elution buffer demonstrated the highest capacity for stabilizing pH shifts. The scalability of this approach was validated using a 10 cm diameter column, where yields remained comparable to small-scale experiments, and elution pool stability was able to be maintained for 72 h at 26°C. These findings establish pH-shifting elution as a scalable, cost-effective method for improving the recovery and stability of low pH-unstable therapeutic antibodies in Protein A chromatography.</p>\",\"PeriodicalId\":12444,\"journal\":{\"name\":\"Frontiers in Bioengineering and Biotechnology\",\"volume\":\"13 \",\"pages\":\"1567923\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12006759/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Bioengineering and Biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.3389/fbioe.2025.1567923\",\"RegionNum\":3,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Bioengineering and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3389/fbioe.2025.1567923","RegionNum":3,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
由于抗体洗脱所需的恶劣酸性条件,蛋白质聚集、变性和效价损失经常发生在蛋白A层析过程中。本研究提出了一种基于pH变化的洗脱策略,通过引入氨基酸基洗脱缓冲液,创造更温和的洗脱环境,提高最终洗脱pH,有效缓解了这些问题。通过优化洗脱前缓冲液和洗脱缓冲液的组合,将洗脱池pH提高到7.2,显著提高了蛋白质的稳定性。在测试的各种洗脱缓冲液中,具有非极性或极性不带电侧链的氨基酸(如亮氨酸、甘氨酸和丝氨酸)表现出最有效的pH转变,导致0.5-2.9个单位的pH变化。此外,使用50 mM Bis-Tris, pH值为7.2作为预洗脱缓冲液,显示出稳定pH值变化的最高能力。该方法的可扩展性使用直径为10 cm的色谱柱进行了验证,其产率与小规模实验相当,洗脱池在26°C下能够保持72小时的稳定性。这些发现确立了ph转移洗脱作为一种可扩展的、具有成本效益的方法,用于提高蛋白a色谱中低ph不稳定治疗性抗体的回收率和稳定性。
Enhancing therapeutic antibody production through amino acid-induced pH shift in Protein A affinity chromatography.
Protein aggregation, denaturation, and loss of potency often occur during Protein A chromatography due to the harsh acidic conditions required for antibody elution. This study presents a pH shift-based elution strategy that effectively mitigates these issues by introducing amino acid-based elution buffers to create a milder elution environment and increase the final elution pH. By optimizing the combination of pre-elution and elution buffers, the elution pool pH was increased up to 7.2, significantly enhancing protein stability. Among various elution buffers tested, amino acids with non-polar or polar uncharged side chains-such as leucine, glycine, and serine-exhibited the most effective pH transition, resulting in 0.5-2.9 units pH shifts. Additionally, the use of 50 mM Bis-Tris, pH 7.2 as a pre-elution buffer demonstrated the highest capacity for stabilizing pH shifts. The scalability of this approach was validated using a 10 cm diameter column, where yields remained comparable to small-scale experiments, and elution pool stability was able to be maintained for 72 h at 26°C. These findings establish pH-shifting elution as a scalable, cost-effective method for improving the recovery and stability of low pH-unstable therapeutic antibodies in Protein A chromatography.
期刊介绍:
The translation of new discoveries in medicine to clinical routine has never been easy. During the second half of the last century, thanks to the progress in chemistry, biochemistry and pharmacology, we have seen the development and the application of a large number of drugs and devices aimed at the treatment of symptoms, blocking unwanted pathways and, in the case of infectious diseases, fighting the micro-organisms responsible. However, we are facing, today, a dramatic change in the therapeutic approach to pathologies and diseases. Indeed, the challenge of the present and the next decade is to fully restore the physiological status of the diseased organism and to completely regenerate tissue and organs when they are so seriously affected that treatments cannot be limited to the repression of symptoms or to the repair of damage. This is being made possible thanks to the major developments made in basic cell and molecular biology, including stem cell science, growth factor delivery, gene isolation and transfection, the advances in bioengineering and nanotechnology, including development of new biomaterials, biofabrication technologies and use of bioreactors, and the big improvements in diagnostic tools and imaging of cells, tissues and organs.
In today`s world, an enhancement of communication between multidisciplinary experts, together with the promotion of joint projects and close collaborations among scientists, engineers, industry people, regulatory agencies and physicians are absolute requirements for the success of any attempt to develop and clinically apply a new biological therapy or an innovative device involving the collective use of biomaterials, cells and/or bioactive molecules. “Frontiers in Bioengineering and Biotechnology” aspires to be a forum for all people involved in the process by bridging the gap too often existing between a discovery in the basic sciences and its clinical application.